2nd, T. M., JK, N., SS, J., EM, U., SI, J., TJ, B., . . . R, L. (2026). Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): A single-arm, phase 3 trial. The Lancet. Oncology, 27(8), 983. https://doi.org/10.1016/S1470-2045(26)00194-4
Παραπομπή σε μορφή Chicago (17η εκδ.)2nd, Tyson MD, et al. "Intravesical Cretostimogene Grenadenorepvec Oncolytic Immunotherapy in High-risk, BCG-unresponsive, Non-muscle-invasive Bladder Cancer with Carcinoma in Situ (BOND-003 Cohort C): A Single-arm, Phase 3 Trial." The Lancet. Oncology 27, no. 8 (2026): 983. https://doi.org/10.1016/S1470-2045(26)00194-4.
Παραπομπή σε μορφή MLA (9th εκδ.)2nd, Tyson MD, et al. "Intravesical Cretostimogene Grenadenorepvec Oncolytic Immunotherapy in High-risk, BCG-unresponsive, Non-muscle-invasive Bladder Cancer with Carcinoma in Situ (BOND-003 Cohort C): A Single-arm, Phase 3 Trial." The Lancet. Oncology, vol. 27, no. 8, 2026, p. 983, https://doi.org/10.1016/S1470-2045(26)00194-4.